Dosimetry and safety of 177Lu PSMA-617 along with polyglutamate parotid gland protector: preliminary results in metastatic castration-resistant prostate cancer patients

医学 前列腺癌 毒性 剂量学 泌尿科 药代动力学 肾 泌尿生殖系统 内科学 核医学 肿瘤科 癌症
作者
Giovanni Paganelli,Anna Sarnelli,Stefano Severi,Maddalena Sansovini,Maria Luisa Belli,Manuela Monti,Flavia Foca,Monica Celli,Silvia Nicolini,Elisa Tardelli,Irene Marini,Federica Matteucci,Melchiore Giganti,Valentina Di Iorio,Ugo De Giorgi
出处
期刊:European Journal of Nuclear Medicine and Molecular Imaging [Springer Science+Business Media]
卷期号:47 (13): 3008-3017 被引量:59
标识
DOI:10.1007/s00259-020-04856-1
摘要

Radioligand therapy (RLT) with 177Lu-PSMA-617 is a promising option for patients with metastatic castration-resistant prostate cancer (mCRPC). The present study was designed to define the safety and initial response to a minimal effective injected activity/cycle of 177Lu-PSMA-617 in mCRPC patients. New protective agents for salivary glands and kidney were co-administered and dosimetry was carried out. A prospective single-arm, open label phase II study on mCRPC was activated at our institute in April 2017. Patients with histologically confirmed advanced mCRPC previously treated with standard life-prolonging agents were enrolled. Folic polyglutamate tablets were orally administered as parotid gland protectors and 500 mL of a 10% mannitol solution was intravenously infused to reduce kidney uptake before the injection of 3.7–5.5 GBq of 177Lu-PSMA-617 repeated four times at interval of 8 weeks. The adsorbed dose calculation was performed with MIRD formalism (OLINDA/EXM software). The Bryant and Day design was used to estimate the sample size taking account of both activity and toxicity. Forty-three eligible patients were evaluated for toxicity and initial response. Dosimetry was carried out in 13 patients. Two (4.8%) patients had G3 and 8 (19.5%) had G2 hematological toxicity. Only 3 (6.9%) patients had mild G1 salivary gland toxicity and 8 (19.5%) had G1 renal toxicity. A decrease of ≥ 30% in prostate-specific antigen (PSA) was achieved after the first cycle in 17 (40.5%) patients, of whom 13 had a PSA decline of >50% after the second cycle. The median adsorbed doses were 0.65 mGy/MBq (range 0.33–2.63) for parotid glands, 0.42 mGy/MBq (0.14–0.81) for kidneys, 0.036 mGy/MBq (0.023–0.067) for red marrow, and 0.038 mGy/MBq (0.018–0.135) for the whole body. In advanced, heavily pre-treated mCRPC patients, 3.7 GBq/cycle of 177Lu-PSMA-617 was safe and produced early biochemical and imaging responses at PSMA whole-body scan post injection. Dosimetry of salivary glands suggests that the co-administration of polyglutamate tablets may reduce salivary gland uptake. EU Clinical Trials Register No.: 2016-002732-32; NCT03454750. Collection and assembly of data: April 2017 and February 2019.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
在望的应助被肖馨余采纳,获得10
刚刚
爱撒娇的朋友完成签到,获得积分10
1秒前
烟花的应助被flash采纳,获得10
2秒前
积极亦竹发布了新的文献求助10
2秒前
xiaxi完成签到,获得积分10
4秒前
ding的应助被xielaoban采纳,获得10
4秒前
5秒前
荼蘼发布了新的文献求助10
5秒前
6秒前
朴实颤完成签到,获得积分10
6秒前
7秒前
7秒前
chuqing发布了新的文献求助10
7秒前
momo完成签到,获得积分10
7秒前
无私的迎松完成签到,获得积分10
9秒前
YYJ完成签到,获得积分10
9秒前
酷波er的应助被积极亦竹采纳,获得10
10秒前
BAEKHYUNLUCKY发布了新的文献求助10
12秒前
12秒前
12秒前
12秒前
尘_发布了新的文献求助10
13秒前
BernardGo发布了新的文献求助10
16秒前
荼蘼发布了新的文献求助10
16秒前
慈祥的丹寒完成签到 ,获得积分10
20秒前
20秒前
冯老三完成签到 ,获得积分10
21秒前
Maestro_S的应助被chuqing采纳,获得10
21秒前
howeVer完成签到 ,获得积分10
21秒前
槟洛完成签到,获得积分10
21秒前
月亮代表我的心完成签到,获得积分10
22秒前
黄大树完成签到,获得积分10
22秒前
高挑的伊完成签到,获得积分10
23秒前
正直的又柔完成签到,获得积分10
24秒前
丘比特的应助被老年学术废物采纳,获得10
24秒前
Long发布了新的文献求助10
24秒前
xixilulixiu完成签到 ,获得积分0
24秒前
渔舟完成签到 ,获得积分10
25秒前
马赛克完成签到,获得积分10
26秒前
荼蘼发布了新的文献求助10
26秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175157
求助须知:如何正确求助?哪些是违规求助? 9566955
关于积分的说明 21789278
捐赠科研通 7769593
什么是DOI,文献DOI怎么找? 3431836
关于科研通互助平台的介绍 2556078
邀请新用户注册赠送积分活动 2477241